Bayer's Rally Hits a Fork in the Road: Analyst Targets Diverge as Glyphosate Hearing Looms
Published on 08/13/2026 at 05:31 | Redaktion boerse-global.de
The market's embrace of Bayer's operational turnaround is running headlong into a legal calendar that refuses to stay put. Shares of the Leverkusen-based life science group have climbed roughly 30 percent since the start of the year, powered by a second-quarter earnings beat that saw the agriculture division and cost-cutting measures deliver, while the pharma segment extended its momentum on the back of newer drug launches. Yet the advance has visibly cooled in recent sessions, with the stock shedding about 2.5 percent over the past week and closing Wednesday down 2.1 percent at EUR 48.14.
The pullback has little to do with fundamentals and everything to do with a courtroom in the United States. A judge has pushed the hearing to approve the USD 7.25 billion Roundup settlement to September 14, following a request from Bayer itself for a brief postponement. The delay does not constitute a setback on the merits, but it extends a period of heightened uncertainty that is already reflected in the equity's behavior.
That uncertainty is quantifiable. The annualized 30-day volatility stands at 26 percent, a level that underscores just how sensitive the stock remains to headlines from the litigation front. As long as the settlement is viewed as an agreed-upon process that is merely awaiting judicial sign-off, the risk remains calculable. Should approval falter or slip again, however, the entire valuation framework shifts.
Wednesday's session neatly encapsulated the divergent views on where Bayer goes from here. Jefferies reaffirmed its "Hold" rating with a price target of EUR 46 — below the current trading level and a signal that not everyone on the Street considers the legal overhang largely resolved. The DZ Bank, by contrast, lifted its fair value to EUR 60 from EUR 54 on August 11, keeping a "Buy" recommendation. Analyst Peter Spengler pointed to operational stabilization, progress on debt reduction, and advances on US legal risks as justification for the more bullish stance.
Should investors sell immediately? Or is it worth buying Bayer?
The chasm between those two targets — EUR 46 on the low end, EUR 60 on the high — reflects two fundamentally different readings of the same situation. One camp emphasizes the operational recovery and the company's own characterization of being "operational on track." The other counsels patience given that the glyphosate litigation remains unresolved. With a market capitalization of EUR 48.36 billion and the stock still trading roughly 20 percent above its 200-day moving average despite the recent giveback, the debate is unlikely to be settled by technical indicators alone. The relative strength index at 52.7 suggests neither overbought nor oversold conditions — a classic consolidation phase following a steep run-up.
The bull case rests on a straightforward premise: if the September hearing produces approval without further complications, a central overhang that has weighed on the valuation for years would finally lift. That scenario would allow the operational improvements from the agriculture and pharma businesses to take center stage, potentially closing the roughly 11 percent gap to the 52-week high of EUR 53.86.
The bear case is equally clear. A postponement of a few weeks is procedurally unremarkable, but it demonstrates how fragile the timeline truly is. Should the September hearing be delayed once more, or should the court demand amendments to the settlement, fresh questions would emerge about the actual financial burden. That outcome would also undermine the recently raised price targets from several houses, which explicitly tied their higher valuations to legal relief.
Until September 14 arrives, Bayer remains a stock caught in an unusually tight embrace between fundamental recovery and residual legal risk. The next concrete test for both scenarios is now firmly on the calendar — and the market will be watching every procedural twist in the interim.
Ad
Bayer Stock: New Analysis - 13 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
